Sino Biopharmaceutical Ltd Stock Performance
| SBHMY Stock | USD 7.25 0.01 0.14% |
The entity has a beta of -0.18, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sino Biopharmaceutica are expected to decrease at a much lower rate. During the bear market, Sino Biopharmaceutica is likely to outperform the market. At this point, Sino Biopharmaceutical has a negative expected return of -0.34%. Please make sure to validate Sino Biopharmaceutica's jensen alpha and daily balance of power , to decide if Sino Biopharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sino Biopharmaceutical Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 10.6 B | |
| Total Cashflows From Investing Activities | -2.5 B | |
| Free Cash Flow | 3.5 B |
Sino |
Sino Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 905.00 in Sino Biopharmaceutical Ltd on November 2, 2024 and sell it today you would lose (180.00) from holding Sino Biopharmaceutical Ltd or give up 19.89% of portfolio value over 90 days. Sino Biopharmaceutical Ltd is currently producing negative expected returns and takes up 1.6824% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Sino, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sino Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sino Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sino Biopharmaceutical Ltd, and traders can use it to determine the average amount a Sino Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SBHMY |
Estimated Market Risk
| 1.68 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sino Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sino Biopharmaceutica by adding Sino Biopharmaceutica to a well-diversified portfolio.
Sino Biopharmaceutica Fundamentals Growth
Sino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sino Biopharmaceutica, and Sino Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sino Pink Sheet performance.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 940.69 M | |||
| Price To Earning | 8.95 X | |||
| Price To Book | 2.53 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B | |||
| EBITDA | 19.87 B | |||
| Cash And Equivalents | 15.67 B | |||
| Cash Per Share | 16.96 X | |||
| Total Debt | 5.21 B | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 32.70 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 1.15 X | |||
| Total Asset | 60.54 B | |||
About Sino Biopharmaceutica Performance
Evaluating Sino Biopharmaceutica's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sino Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sino Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States.Things to note about Sino Biopharmaceutical performance evaluation
Checking the ongoing alerts about Sino Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sino Biopharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sino Biopharmaceutica generated a negative expected return over the last 90 days |
- Analyzing Sino Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sino Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Sino Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sino Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sino Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sino Biopharmaceutica's pink sheet. These opinions can provide insight into Sino Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.